Загрузка...
Bortezomib for the treatment of non-Hodgkin’s lymphoma
INTRODUCTION: Bortezomib, the first proteasome inhibitor (PI) to be evaluated in humans, is approved in the USA and Europe for the treatment of patients with multiple myeloma, and in the USA for patients with relapsed mantle cell lymphoma (MCL). AREAS COVERED: This review examines the role of bortez...
Сохранить в:
| Опубликовано в: : | Expert Opin Pharmacother |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4856151/ https://ncbi.nlm.nih.gov/pubmed/25263936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.965142 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|